ADD/ADHD News

ATLANTA — Data presented here showed adults with attention-deficit/hyperactivity disorder were prescribed combination treatment with a long-acting monotherapy, suggesting that currently available medications may not meet patient needs.

A recent clinical review in JAMA reported that evidence supporting the use of methylphenidate among adolescents for treatment of attention-deficit/hyperactivity disorder is of very low quality and should be reconsidered for future therapy guidelines.

The NLS Pharma Group recently announced submission of an Investigational New Drug Application to the FDA to study mazindol for attention-deficit/hyperactivity disorder in adults.

Addictive use of video games and social media was significantly associated with mental health disorder symptoms, according to recent findings.

Recent findings from the CDC indicated medication was more common than psychological services for treatment of attention-deficit/hyperactivity disorder in children aged 2 to 5 years, despite guidelines that recommend psychological services as first-line treatment for attention-deficit/hyperactivity disorder in young children.

BALTIMORE — Children living in poverty experienced significantly higher rates of asthma and attention-deficit/hyperactivity disorder compared to wealthier children, according to recent study findings presented at the Pediatric Academic Societies Meeting.

BALTIMORE — Mental health diagnoses and care significantly increased among military-connected children within the last 15 years, according to data presented at the Pediatric Academic Societies Meeting.

Data presented at the American Academy of Neurology Annual Meeting indicated stimulant medication was effective and safe for treatment of attention-deficit/hyperactivity disorder in children with epilepsy.

Tris Pharma Inc. recently announced the launch of Dyanavel XR, extended-release oral suspension, CII, for attention-deficit/hyperactivity disorder in children aged 6 years and older.

Data presented at the American Academy of Neurology Annual Meeting indicated certain dosages of extended-release molindone were effective for impulsive aggression in children with attention-deficit/hyperactivity disorder already receiving optimized stimulant monotherapy and behavioral therapy.